Anti-TNF Use Prior to Bowel Resection Is Not Associated With 30 Day Postoperative Complications: A National Database Study. Issue 2 (2nd August 2019)

• Record Type: Journal Article
• Authors: Pirkle, Sean; Bhattacharjee, Sarah; Reddy, Srikanth; Shi, Lewis L; Lee, Michael J; Dalal, Sushila
• Is Part Of: Crohn's & colitis 360. Volume 1:Issue 2(2019)
• Publication Date: 2019-08-02
• Subjects: IBD -- anti-TNF therapy -- bowel resection -- postoperative complications; Crohn's disease -- Periodicals; Colitis -- Periodicals; 616.344
• DOI: 10.1093/crocol/otz012
• Languages: English
• ISSNs: 2631-827X

Abstract

Abstract: Background: Inflammatory bowel disease (IBD) patients are often counseled to pause anti-tumor necrosis factor (TNF) therapy before surgery. Here, we assessed the effects of preoperative anti-TNF treatment on bowel resection complications. Methods: A national database analysis was performed. IBD patients who underwent bowel resection were included. Patients using preoperative anti-TNF were stratified by treatment regimen. Complication rates were compared between these groups and a control group with no anti-TNF history. Results: Twenty thousand and sixty-eight patients matched our criteria. We observed no significant differences between preoperative anti-TNF regimens and postoperative bowel resection complications. Conclusions: These data suggest that anti-TNF therapy may safely be continued prior to bowel resection. Lay Summary: The authors used a national database to gather a large number of patients with inflammatory bowel disease to study the effect of preoperative (before surgery) exposure to biologic therapy with postoperative (after surgery) complications following intestinal resection for inflammatory bowel disease.